GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Net Income Including Noncontrolling Interests

Geron (STU:GON) Net Income Including Noncontrolling Interests : €-186.04 Mil (TTM As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Geron Net Income Including Noncontrolling Interests?

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Geron's Net Income Including Noncontrolling Interests for the three months ended in Mar. 2024 was €-50.96 Mil. Its Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 was €-186.04 Mil.

Geron Net Income Including Noncontrolling Interests Historical Data

The historical data trend for Geron's Net Income Including Noncontrolling Interests can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Geron Net Income Including Noncontrolling Interests Chart

Geron Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income Including Noncontrolling Interests
Get a 7-Day Free Trial Premium Member Only Premium Member Only -61.69 -62.16 -102.76 -133.96 -168.84

Geron Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Including Noncontrolling Interests Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.61 -45.44 -41.98 -47.66 -50.96

Geron Net Income Including Noncontrolling Interests Calculation

Net Income Including Noncontrolling Interests is the net income of the group after the adjustment of all expenses and benefit. It includes the net income (loss) attributable to noncontrolling and redeemable noncontrolling interests and the net income (loss) attributable to the company.

Net Income Including Noncontrolling Interests for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-186.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geron Net Income Including Noncontrolling Interests Related Terms

Thank you for viewing the detailed overview of Geron's Net Income Including Noncontrolling Interests provided by GuruFocus.com. Please click on the following links to see related term pages.

Geron (STU:GON) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geron Corp (STU:GON) » Definitions » Net Income Including Noncontrolling Interests
Comparable Companies
KYMR VERA BEAM RXRX CGON RCKT ADMA RYTM CPRX NVAX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
GERN:USA
Address
919 East Hillsdale Boulevard, Suite 250, Foster City, CA, USA, 94404
Website
https://www.geron.com
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's leading drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses global rights to this drug. the company operates as a single segment, the development of therapeutic products for oncology.

Geron (STU:GON) Headlines

No Headlines